Clevudine

• Description:

  Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice[1][2][3].

• Product Name Alternative:

  L-FMAU

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  DNA/RNA Synthesis; HBV; Orthopoxvirus

• Type:

  Oligonucleotides

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/Clevudine.html

• Purity:

  99.93

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

• Smiles:

  O[C@@H]1[C@@H](F)[C@@H](N2C(NC(C(C)=C2)=O)=O)O[C@H]1CO

• Molecular Formula:

  C10H13FN2O5

• Molecular Weight:

  260.22

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Asselah T, et al. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008;17 (12) :1963-1974.|[2]Yoo BC, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46 (4) :1041-1048.|[3]Smee DF, et, al. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19 (3) :115-24.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Oligonucleotides

• Clinical Information:

  Launched

• CAS Number:

  163252-36-6